Uncategorized
Copay assistance programs not solution to high drug prices
Copay assistance, a seeming resolution to the drug pricing dilemma, is actually the problem, according to a commentary published in Annals of Internal Medicine.The 600% price hike of Mylan’s EpiPen over a period of 8 years is the most recent outcry regarding expensive drug prices, Peter A. Ubel, MD, of Duke University and Peter B. Bach, MD, of Memorial Sloan Kettering Cancer Center, wrote in their commentary.